• 1. An atomic scale study of defects in Co2FeAl
  Ravi Kumar Yadav,R. Govindaraj Phys. Chem. Chem. Phys., 2020,22, 26876-26886
• 2. An atlas of endohedral Sc2S cluster fullerenes?
  Li-Hua Gan,Rui Wu,Jian-Lei Tian,Patrick W. Fowler Phys. Chem. Chem. Phys., 2017,19, 419-425
• 3. An algal process treatment combined with the Fenton reaction for high concentrations of amoxicillin and cefradine
  Haitao Li,Yu Pan,Zhizhi Wang,Shan Chen,Ruixin Guo,Jianqiu Chen RSC Adv., 2015,5, 100775-100782
• 4. An Appraisal of pH triggered Bacitracin drug release, through composite hydrogel systems
  RabailGul,MariamMir,MurtazaNAli
• 5. An asymmetric supercapacitor based on controllable WO3 nanorod bundle and alfalfa-derived porous carbon?
  Kanjun Sun,Fengting Hua,Shuzhen Cui,Yanrong Zhu,Hui Peng,Guofu Ma RSC Adv., 2021,11, 37631-37642

Recent Advances in the Study of N-[(1-benzylpiperidin-4-yl)methyl]-N-(pyridin-3-ylmethyl)amine (CAS: 921124-94-9)

N-[(1-benzylpiperidin-4-yl)methyl]-N-(pyridin-3-ylmethyl)amine (CAS: 921124-94-9) is a chemical compound that has garnered significant attention in the field of chemical biology and medicinal chemistry due to its potential therapeutic applications. Recent studies have focused on elucidating its pharmacological properties, synthetic pathways, and biological activities, particularly in the context of central nervous system (CNS) disorders and cancer therapeutics. This research brief aims to summarize the latest findings related to this compound, providing a comprehensive overview of its current status in scientific research.

The compound's structure features a benzylpiperidine moiety linked to a pyridinylmethylamine group, which is believed to contribute to its unique binding affinity for specific biological targets. Recent synthetic efforts have optimized the production of N-[(1-benzylpiperidin-4-yl)methyl]-N-(pyridin-3-ylmethyl)amine, yielding higher purity and scalability, which is crucial for further pharmacological evaluations. Advanced spectroscopic techniques, including NMR and mass spectrometry, have been employed to confirm the compound's structural integrity and purity.

In vitro studies have demonstrated that N-[(1-benzylpiperidin-4-yl)methyl]-N-(pyridin-3-ylmethyl)amine exhibits promising activity as a modulator of neurotransmitter receptors, particularly those involved in dopaminergic and serotonergic pathways. These findings suggest potential applications in treating neurological disorders such as Parkinson's disease and depression. Additionally, preliminary data indicate that the compound may possess anti-proliferative effects against certain cancer cell lines, warranting further investigation into its mechanisms of action and therapeutic potential.

Recent pharmacokinetic studies have explored the compound's absorption, distribution, metabolism, and excretion (ADME) profiles, providing valuable insights into its bioavailability and potential side effects. These studies have utilized advanced analytical methods, such as high-performance liquid chromatography (HPLC) and liquid chromatography-mass spectrometry (LC-MS), to track the compound's behavior in biological systems. The results indicate moderate oral bioavailability and a favorable half-life, making it a viable candidate for further drug development.

Despite these promising findings, challenges remain in the clinical translation of N-[(1-benzylpiperidin-4-yl)methyl]-N-(pyridin-3-ylmethyl)amine. Issues such as selectivity, toxicity, and off-target effects need to be addressed through rigorous preclinical testing. Future research directions may include structural optimization to enhance efficacy and reduce adverse effects, as well as comprehensive in vivo studies to validate its therapeutic potential. Collaborative efforts between academic institutions and pharmaceutical companies will be essential to advance this compound toward clinical trials.

In conclusion, N-[(1-benzylpiperidin-4-yl)methyl]-N-(pyridin-3-ylmethyl)amine (CAS: 921124-94-9) represents a promising candidate for further investigation in the fields of neuroscience and oncology. Its unique chemical structure and preliminary biological activities highlight its potential as a therapeutic agent. Continued research efforts will be crucial to fully understand its mechanisms of action and to overcome the challenges associated with its development. This brief underscores the importance of interdisciplinary collaboration in advancing the frontiers of chemical biology and medicinal chemistry.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)